Effet d’un traitement par hydroxychloroquine prescrit comme traitement de fond de rhumatismes inflammatoires chroniques ou maladies auto-immunes systémiques sur les tests diagnostiques et l’évolution de l’infection à SARS CoV-2: étude de 871 patients
et al., Revue du Rhumatisme, doi:10.1016/j.rhum.2021.09.004 (date from earlier preprint)
, Effet d’un traitement par hydroxychloroquine prescrit comme traitement de fond de rhumatismes inflammatoires.., Revue du Rhumatisme, doi:10.1016/j.rhum.2021.09.004 (date from earlier preprint)
Retrospective 71 chronic HCQ patients compared with 191 matched controls, analyzing only those with a highly suspected or confirmed diagnosis of COVID-19. No significant difference was found in outcomes, however matching failed with extreme confounding - 77.5% of HCQ patients with systemic autoimmune diseases vs. 21.5% of control patients.Other research shows that the risk of COVID-19 for systemic autoimmune disease patients is much higher overall, Ferri et al. show OR 4.42, p<0.001 [Ferri].
This study is excluded in the after exclusion results of meta
analysis:
not fully adjusting for the different baseline risk of systemic autoimmune patients; significant unadjusted confounding possible; excessive unadjusted differences between groups.
|
risk of death, 16.6% higher, RR 1.17, p = 0.80, treatment 4 of 68 (5.9%), control 12 of 183 (6.6%), adjusted per study, odds ratio converted to relative risk.
|
|
risk of death/ICU, 78.2% higher, RR 1.78, p = 0.21, treatment 8 of 71 (11.3%), control 18 of 191 (9.4%), adjusted per study, odds ratio converted to relative risk.
|
|
risk of hospitalization, 44.9% higher, RR 1.45, p = 0.12, treatment 24 of 71 (33.8%), control 53 of 191 (27.7%), adjusted per study, odds ratio converted to relative risk.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Trefond et al., 27 Jan 2021, retrospective, France, peer-reviewed, 21 authors.
Abstract: Since January 2020 Elsevier has created a COVID-19 resource centre with
free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the
company's public news and information website.
Elsevier hereby grants permission to make all its COVID-19-related
research that is available on the COVID-19 resource centre - including this
research content - immediately available in PubMed Central and other
publicly funded repositories, such as the WHO COVID database with rights
for unrestricted research re-use and analyses in any form or by any means
with acknowledgement of the original source. These permissions are
granted for free by Elsevier for as long as the COVID-19 resource centre
remains active.
Journal Pre-proof
Effet d’un traitement par hydroxychloroquine prescrit comme traitement
de fond de rhumatismes inflammatoires chroniques ou maladies
auto-immunes systémiques sur les tests diagnostiques et l’évolution de
l’infection à SARS CoV-2: étude de 871 patients
Ludovic Trefond Elodie Drumez Marc Andre Nathalie
Costedoat-Chalumeau Raphaèle Seror Mathilde Devaux
Emmanuelle Dernis Yannick Dieudonne Soumaya El Mahou Aurelia
Lanteri Isabelle Melki Viviane Queyrel Mathilde Roumier Jean
Schmidt Thomas Barnetche Thierry Thomas Patrice Cacoub
Alexandre Belot Olivier Aumaitre Christophe Richez Eric Hachulla,
FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium et
contributeurs
PII:
S1169-8330(21)00248-9
DOI:
https://doi.org/doi:10.1016/j.rhum.2021.09.004
Reference:
REVRHU 5360
To appear in:
Revue du rhumatisme
Please cite this article as: Trefond L, Drumez E, Andre M, Costedoat-Chalumeau N, Seror R,
Devaux M, Dernis E, Dieudonne Y, Mahou SE, Lanteri A, Melki I, Queyrel V, Roumier M,
Schmidt J, Barnetche T, Thomas T, Cacoub P, Belot A, Aumaitre O, Richez C, Hachulla E,
Effet d’un traitement par hydroxychloroquine prescrit comme traitement de fond de
rhumatismes inflammatoires chroniques ou maladies auto-immunes systémiques sur les tests
diagnostiques et l’évolution de l’infection à SARS CoV-2: étude de 871 patients, Revue du
rhumatisme (2021), doi: https://doi.org/10.1016/j.rhum.2021.09.004
This is a PDF file of an article that has undergone enhancements after acceptance, such as
the addition of a cover page and metadata, and formatting for readability, but it is not yet the
definitive version of record. This version will undergo additional copyediting, typesetting and
review before it is published in its final form, but we are providing this version to give early
visibility of the article. Please note that, during the production process, errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal
pertain.
© 2020 Published by Elsevier.
Effet d’un traitement par hydroxychloroquine prescrit comme traitement de fond de
rhumatismes inflammatoires chroniques ou maladies auto-immunes systémiques sur les
tests diagnostiques et l’évolution de l’infection à SARS CoV-2 : étude de 871 patients
Ludovic Trefond,1 Elodie Drumez,2 Marc Andre,1 Nathalie Costedoat-Chalumeau,3 Raphaèle Seror,4
Mathilde Devaux,5 Emmanuelle Dernis,6 Yannick Dieudonne,7 Soumaya El Mahou,8 Aurelia Lanteri,9
Isabelle Melki,10 Viviane Queyrel,11 Mathilde Roumier,12 Jean Schmidt,13 Thomas Barnetche,14
Thierry Thomas,15 Patrice Cacoub,16 Alexandre Belot,17 Olivier Aumaitre,1 Christophe Richez,14 Eric
Hachulla,18 FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium et..
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.